NO20061789L - Aminopyridinderivater som induserbare NO-syntaseinhibitorer - Google Patents

Aminopyridinderivater som induserbare NO-syntaseinhibitorer

Info

Publication number
NO20061789L
NO20061789L NO20061789A NO20061789A NO20061789L NO 20061789 L NO20061789 L NO 20061789L NO 20061789 A NO20061789 A NO 20061789A NO 20061789 A NO20061789 A NO 20061789A NO 20061789 L NO20061789 L NO 20061789L
Authority
NO
Norway
Prior art keywords
inducible
synthase inhibitors
aminopyridine derivatives
aminopyridine
derivatives
Prior art date
Application number
NO20061789A
Other languages
English (en)
Norwegian (no)
Inventor
Manfrid Eltze
Rainer Boer
Degenhard Marx
Thomas Fuchss
Wolf-Ruediger Ulrich
Ulrich Graedler
Ruediger Nave
Andreas Strub
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of NO20061789L publication Critical patent/NO20061789L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20061789A 2003-10-01 2006-04-24 Aminopyridinderivater som induserbare NO-syntaseinhibitorer NO20061789L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03022040 2003-10-01
PCT/EP2004/052373 WO2005061496A1 (en) 2003-10-01 2004-09-30 Aminopyridine-derivatives as inductible no-synthase inhibitors

Publications (1)

Publication Number Publication Date
NO20061789L true NO20061789L (no) 2006-04-24

Family

ID=34707254

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061789A NO20061789L (no) 2003-10-01 2006-04-24 Aminopyridinderivater som induserbare NO-syntaseinhibitorer

Country Status (16)

Country Link
US (3) US7317021B2 (sr)
EP (1) EP1670798A1 (sr)
JP (1) JP2007507464A (sr)
KR (1) KR20060092219A (sr)
CN (1) CN100415746C (sr)
AU (1) AU2004303515A1 (sr)
BR (1) BRPI0415034A (sr)
CA (1) CA2540230A1 (sr)
EA (1) EA200600601A1 (sr)
IL (1) IL173628A0 (sr)
MX (1) MXPA06003345A (sr)
NO (1) NO20061789L (sr)
NZ (1) NZ546394A (sr)
RS (1) RS20060206A (sr)
WO (1) WO2005061496A1 (sr)
ZA (1) ZA200601140B (sr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2540083A1 (en) 2003-10-01 2005-04-07 Altana Pharma Ag Imidazopyridine-derivatives as inductible no-synthase inhibitors
US7279488B2 (en) 2003-10-01 2007-10-09 Nycomed Gmbh Imidazopyridine-derivatives as inducible no-synthase inhibitors
JP2007507463A (ja) 2003-10-01 2007-03-29 アルタナ　ファルマ　アクチエンゲゼルシャフト 誘導性ＮＯシンターゼ阻害剤としてのイミダゾ［４，５−ｂ］ピリジン誘導体
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
JP2008534555A (ja) 2005-03-31 2008-08-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング ｉＮＯＳインヒビターとして有用なイミダゾピリジン誘導体
US8461189B2 (en) * 2007-06-27 2013-06-11 Merck Sharp & Dohme Corp. Pyridyl derivatives as histone deacetylase inhibitors
US20100278751A1 (en) * 2009-04-30 2010-11-04 Washington University Radiolabeled 2-amino-4-alkyl-6-(haloalkyl)pyridine compounds and their use in diagnostic imaging
JP5911476B2 (ja) 2010-05-26 2016-04-27 スノビオン プハルマセウトイカルス インコーポレイテッド ヘテロアリール化合物及びその使用方法
GB201512635D0 (en) 2015-07-17 2015-08-26 Ucl Business Plc Uses of therapeutic compounds
WO2018211808A1 (ja) 2017-05-15 2018-11-22 ソニー株式会社 照明装置、および表示装置
US12240815B2 (en) * 2020-02-24 2025-03-04 Northwestern University Potent and selective human neuronal nitric oxide synthase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE418966B (sv) 1974-02-18 1981-07-06 Haessle Ab Analogiforfarande for framstellning av foreningar med magsyrasekretionsinhiberande verkan
US4045564A (en) 1974-02-18 1977-08-30 Ab Hassle Benzimidazole derivatives useful as gastric acid secretion inhibitors
GB8307865D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
AU650953B2 (en) * 1991-03-21 1994-07-07 Novartis Ag Inhaler
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
JP4448695B2 (ja) 2002-03-27 2010-04-14 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規アルコキシピリジン−誘導体
CA2540083A1 (en) 2003-10-01 2005-04-07 Altana Pharma Ag Imidazopyridine-derivatives as inductible no-synthase inhibitors
US7279488B2 (en) 2003-10-01 2007-10-09 Nycomed Gmbh Imidazopyridine-derivatives as inducible no-synthase inhibitors
JP2007507463A (ja) 2003-10-01 2007-03-29 アルタナ　ファルマ　アクチエンゲゼルシャフト 誘導性ＮＯシンターゼ阻害剤としてのイミダゾ［４，５−ｂ］ピリジン誘導体
CN1856494A (zh) 2003-10-01 2006-11-01 奥坦纳医药公司 作为诱导型no－合酶抑制剂的咪唑并吡啶类衍生物

Also Published As

Publication number Publication date
US7781453B2 (en) 2010-08-24
KR20060092219A (ko) 2006-08-22
EP1670798A1 (en) 2006-06-21
US20070043072A1 (en) 2007-02-22
NZ546394A (en) 2009-08-28
WO2005061496A1 (en) 2005-07-07
CN100415746C (zh) 2008-09-03
US20100280002A1 (en) 2010-11-04
US20080176894A1 (en) 2008-07-24
EA200600601A1 (ru) 2006-10-27
WO2005061496A8 (en) 2006-02-16
MXPA06003345A (es) 2006-06-08
AU2004303515A1 (en) 2005-07-07
BRPI0415034A (pt) 2006-12-12
CA2540230A1 (en) 2005-07-07
HK1096968A1 (zh) 2007-06-15
JP2007507464A (ja) 2007-03-29
RS20060206A (sr) 2008-08-07
ZA200601140B (en) 2007-05-30
IL173628A0 (en) 2006-07-05
CN1856493A (zh) 2006-11-01
US7317021B2 (en) 2008-01-08

Similar Documents

Publication Publication Date Title
NO20053647L (no) Pyrazolopyridinderivater
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
NO20050199L (no) Azadisyklo-oktan og nonanderivater med DDP-IV-inhiberende aktivitet
NO20073921L (no) Triazoloftalaziner
DE60225671D1 (de) Pharmazeutisch wirksame piperidinderivate
NO20050828L (no) lndol-3-svovelderivater
NO20070731L (no) Heterocykliske forbindelser.
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
NO20064418L (no) Nye amido-substituerte hydroksy-6-fenylfenantridiner
MXPA05010875A (es) Derivados de piperazina como inhibidores de renina.
NO20082105L (no) Pyrazoloisokinolinderivater
NO20064415L (no) Nye amido-substituerte hydroksy-6-fenylfenantridiner og deres anvendelse som PDE4-inhibitorer
NO20070089L (no) DPP-IV inhibitorer
NO20061789L (no) Aminopyridinderivater som induserbare NO-syntaseinhibitorer
NO20071805L (no) Alkylidentetrahydronaftalenderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere.
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
NO20060963L (no) Nikotinamidderivater anvendelige som PDE4-inhibitorer
NO20080144L (no) Spiro-benzimidazoler som inhibitorer av magesyre og sekresjon
NO20063220L (no) Tricykliske imidazopyridiner for anvendelse som gastriske sekresjonsinhibitorer
NO20064632L (no) Tricykliske imidazopyridiner
NO20064491L (no) Nye difluomtoksysubstituee hydroksy-6-fenylfenantridiner og deres anvendelse som PDE4-inhibitorer
NO20055657L (no) Nye bioisostaererav aktinonin
NO20061344L (no) Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer
NO20055749L (no) Sulfamat benzotiofenderivater som steroid sulfatase inhibitorer

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

FC2A Withdrawal, rejection or dismissal of laid open patent application